Literature DB >> 15293284

Functional significance of S6K overexpression in meningioma progression.

Ezequiel I Surace1, Eriks Lusis, Carrie A Haipek, David H Gutmann.   

Abstract

One common genetic change in anaplastic meningiomas is amplification of chromosome 17q23 containing the S6 kinase (S6K) gene. We show, for the first time to our knowledge, increased S6K mRNA expression in anaplastic meningiomas compared with benign tumors. To evaluate S6K as a candidate meningioma progression gene, we generated IOMM-Lee human meningioma cell lines overexpressing S6K. Whereas no effect of S6K overexpression on meningioma cell growth, motility, or adhesion was observed in vitro, S6K overexpression resulted in increased tumor size in vivo. Collectively, these results suggest that S6K is functionally important for meningioma progression and may represent a target for future meningioma therapy. Copyright 2004 American Neurological Association

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293284     DOI: 10.1002/ana.20201

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

2.  Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients.

Authors:  Pin Dong Li; Wen Jie Zhang; Mei Ying Zhang; Lin Jing Yuan; Yin Lian Cha; Xiao Fang Ying; Gang Wu; Hui Yun Wang
Journal:  Med Oncol       Date:  2012-06-10       Impact factor: 3.064

Review 3.  Pathological classification and molecular genetics of meningiomas.

Authors:  Christian Mawrin; Arie Perry
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

4.  Fatty acid synthase as a novel target for meningioma therapy.

Authors:  Daniela Haase; Stefan Schmidl; Christian Ewald; Rolf Kalff; Christian Huebner; Raimund Firsching; Gerburg Keilhoff; Matthias Evert; Werner Paulus; David H Gutmann; Anita Lal; Christian Mawrin
Journal:  Neuro Oncol       Date:  2010-02-05       Impact factor: 12.300

5.  M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

Authors:  Andreas Machl; Erik W Wilker; Hui Tian; Xiaohong Liu; Patricia Schroeder; Anderson Clark; Bayard R Huck
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 6.  mTOR signalling in human cancer.

Authors:  J Albanell; A Dalmases; A Rovira; F Rojo
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.405

Review 7.  The mTOR signaling pathway as a treatment target for intracranial neoplasms.

Authors:  Doreen Pachow; Wolfgang Wick; David H Gutmann; Christian Mawrin
Journal:  Neuro Oncol       Date:  2014-08-27       Impact factor: 12.300

Review 8.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

9.  Diabetes, use of metformin, and the risk of meningioma.

Authors:  Corinna Seliger; Christoph R Meier; Claudia Becker; Susan S Jick; Martin Proescholdt; Ulrich Bogdahn; Peter Hau; Michael F Leitzmann
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

10.  Protein Kinase A Distribution in Meningioma.

Authors:  Antonio Caretta; Luca Denaro; Domenico D'Avella; Carla Mucignat-Caretta
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.